Increased Expression of SPRY4-IT1 Predicts Poor Prognosis and Promotes Tumor Growth and Metastasis in Bladder Cancer

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2015 May 15

PMID 25973088

Citations 39

Authors

Xiao-Lei Zhao

Zhen-Hua Zhao

Wen-Chao Xu

Jun-Qing Hou

Xin-Yi Du

Affiliations

Soon will be listed here.

Abstract

Introduction: long non-coding RNAs (lncRNAs) are emerging as new regulators in the cancer paradigm, the involvement of lncRNAs in urothelial carcinoma of the bladder (UCB) is just beginning to be studied. In this study, we focused on lncRNA SPRY4-IT1 and investigated its expression pattern, clinical significance, and biological function in UCB.

Methods: SPRY4-IT1 expression in UCB tissues was examined by quantitative Real-time PCR (qRT-PCR) and its correlation with clinicopathological features and patient prognosis was later analyzed. Moreover, in vitro assays were performed to explore its role in bladder cancer progression.

Results: SPRY4-IT1 expression was elevated in UCB tissues, and SPRY4-IT1 levels were highly positively correlated with histological grade, tumor stage, and lymph node metastasis and reduced overall survival. A multivariate analysis showed that SPRY4-IT1 expression is an independent prognostic factor of overall survival in patients with UCB. Additionally, the results of in vitro assays showed that the suppression of SPRY4-IT1 expression in bladder cancer cells significantly inhibit cell proliferation, migration, and invasion.

Conclusions: Our data suggested that lncRNA SPRY4-IT1 is a novel molecule involved in bladder cancer progression, which provide a potential prognostic biomarker and therapeutic target.

Citing Articles

Long non-coding RNAs: regulators of autophagy and potential biomarkers in therapy resistance and urological cancers.

Wang S, Bai Y, Ma J, Qiao L, Zhang M Front Pharmacol. 2024; 15:1442227.

PMID: 39512820 PMC: 11540796. DOI: 10.3389/fphar.2024.1442227.

Non-coding RNAs as therapeutic targets in cancer and its clinical application.

Leng X, Zhang M, Xu Y, Wang J, Ding N, Yu Y J Pharm Anal. 2024; 14(7):100947.

PMID: 39149142 PMC: 11325817. DOI: 10.1016/j.jpha.2024.02.001.

Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer.

Xiao X, Peng J, Chen Y, Lu X, Sun W, Xiao W Iran J Public Health. 2023; 52(6):1225-1237.

PMID: 37484159 PMC: 10362833. DOI: 10.18502/ijph.v52i6.12988.

A Review on the Role of SPRY4-IT1 in the Carcinogenesis.

Ghafouri-Fard S, Khoshbakht T, Taheri M, Shojaei S Front Oncol. 2022; 11:779483.

PMID: 35096580 PMC: 8792834. DOI: 10.3389/fonc.2021.779483.

Emerging Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis.

Zhang C, Hu J, Li H, Ma H, Othmane B, Ren W Front Oncol. 2021; 11:648968.

PMID: 33869048 PMC: 8044933. DOI: 10.3389/fonc.2021.648968.

References

Yang F, Huang J, Liu M, Yang F, Li W, Wang G . Argonaute 2 is up-regulated in tissues of urothelial carcinoma of bladder. Int J Clin Exp Pathol. 2014; 7(1):340-7. PMC: 3885489. View

Ma M, Kong X, Weng M, Zhang M, Qin Y, Gong W . Long non-coding RNA-LET is a positive prognostic factor and exhibits tumor-suppressive activity in gallbladder cancer. Mol Carcinog. 2014; 54(11):1397-406. DOI: 10.1002/mc.22215. View

Xie H, Wu Q, Zhu B, Chen F, Ji L, Li S . Long noncoding RNA SPRY4-IT1 is upregulated in esophageal squamous cell carcinoma and associated with poor prognosis. Tumour Biol. 2014; 35(8):7743-54. DOI: 10.1007/s13277-014-2013-y. View

Stein J, Lieskovsky G, Cote R, Groshen S, Feng A, Boyd S . Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19(3):666-75. DOI: 10.1200/JCO.2001.19.3.666. View

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

Bolenz C, Lotan Y . Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol. 2008; 5(12):676-85. DOI: 10.1038/ncpuro1259. View

Mourtada-Maarabouni M, Pickard M, Hedge V, Farzaneh F, Williams G . GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene. 2008; 28(2):195-208. DOI: 10.1038/onc.2008.373. View

Ponting C, Oliver P, Reik W . Evolution and functions of long noncoding RNAs. Cell. 2009; 136(4):629-41. DOI: 10.1016/j.cell.2009.02.006. View

Costa F . Non-coding RNAs: Meet thy masters. Bioessays. 2010; 32(7):599-608. DOI: 10.1002/bies.200900112. View

10.

Stenzl A, Cowan N, De Santis M, Kuczyk M, Merseburger A, Ribal M . Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol. 2011; 59(6):1009-18. DOI: 10.1016/j.eururo.2011.03.023. View

11.

Khaitan D, Dinger M, Mazar J, Crawford J, Smith M, Mattick J . The melanoma-upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res. 2011; 71(11):3852-62. DOI: 10.1158/0008-5472.CAN-10-4460. View

12.

Wang K, Chang H . Molecular mechanisms of long noncoding RNAs. Mol Cell. 2011; 43(6):904-14. PMC: 3199020. DOI: 10.1016/j.molcel.2011.08.018. View

13.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

14.

Geng Y, Xie S, Li Q, Ma J, Wang G . Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression. J Int Med Res. 2012; 39(6):2119-28. DOI: 10.1177/147323001103900608. View

15.

Prensner J, Chinnaiyan A . The emergence of lncRNAs in cancer biology. Cancer Discov. 2011; 1(5):391-407. PMC: 3215093. DOI: 10.1158/2159-8290.CD-11-0209. View

16.

Siegel R, Naishadham D, Jemal A . Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1):11-30. DOI: 10.3322/caac.21166. View

17.

Gutschner T, Hammerle M, Eissmann M, Hsu J, Kim Y, Hung G . The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res. 2012; 73(3):1180-9. PMC: 3589741. DOI: 10.1158/0008-5472.CAN-12-2850. View

18.

Han Y, Liu Y, Gui Y, Cai Z . Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol. 2012; 107(5):555-9. DOI: 10.1002/jso.23264. View

19.

Zou Y, Jiang Z, Yu X, Sun M, Zhang Y, Zuo Q . Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8SV/neo. PLoS One. 2013; 8(11):e79598. PMC: 3819274. DOI: 10.1371/journal.pone.0079598. View

20.

Zhang H, Yang F, Yan Y, Che J, Zheng J . High expression of long non-coding RNA SPRY4-IT1 predicts poor prognosis of clear cell renal cell carcinoma. Int J Clin Exp Pathol. 2014; 7(9):5801-9. PMC: 4203192. View